Uptake of screening and prevention in women at very high risk of breast cancer

被引：39

作者：

Evans, DGR

Lalloo, F

Shenton, A

Boggis, C

Howell, A

机构：

[1] St Marys Hosp, Dept Med Genet, Manchester M13 0JH, Lancs, England

[2] Withington Hosp, Nightingale Breast Screening Ctr, Manchester, Lancs, England

[3] Christie Hosp, CRC Dept Med Oncol, Manchester, Lancs, England

来源：

LANCET | 2001年 / 358卷 / 9285期

关键词：

D O I：

10.1016/S0140-6736(01)06039-1

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Management of women at high lifetime risk of familial breast cancer is hampered because of limited data concerning the appropriateness of treatment options. Over the past 8 years women at very high (>40%) lifetime risk of breast cancer have had the option of entering two chemoprevention treatment trials, a magnetic resonance imaging (MRI) breast screening study, or a risk-reducing mastectomy (RRM) study. Only 10% of eligible women have entered one of the chemotherapy trials with a similar proportion opting for RRM (>50% in mutation carriers) compared with 60% opting for MRI screening. Future chemotherapy trials will have to be designed to address this poor recruitment.

引用

页码：889 / 890

页数：2

共 6 条

[1]

CLAUS EB, 1994, CANCER, V73, P643, DOI 10.1002/1097-0142(19940201)73:3<643::AID-CNCR2820730323>3.0.CO

[2]

2-5

[3] Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families [J].

Ford, D ;

Easton, DF ;

Stratton, M ;

Narod, S ;

Goldgar, D ;

Devilee, P ;

Bishop, DT ;

Weber, B ;

Lenoir, G ;

Chang-Claude, J ;

Sobol, H ;

Teare, MD ;

Struewing, J ;

Arason, A ;

Scherneck, S ;

Peto, J ;

Rebbeck, TR ;

Tonin, P ;

Neuhausen, S ;

Barkardottir, R ;

Eyfjord, J ;

Lynch, H ;

Ponder, BAJ ;

Gayther, SA ;

Birch, JM ;

Lindblom, A ;

Stoppa-Lyonnet, D ;

Bignon, Y ;

Borg, A ;

Hamann, U ;

Haites, N ;

Scott, RJ ;

Maugard, CM ;

Vasen, H .

AMERICAN JOURNAL OF HUMAN GENETICS, 1998, 62 (03) :676-689

[4]

Grann VR, 2000, CANCER J SCI AM, V6, P13

[5] Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer [J].

Hartmann, LC ;

Schaid, DJ ;

Woods, JE ;

Crotty, TP ;

Myers, JL ;

Arnold, PG ;

Petty, PM ;

Sellers, TA ;

Johnson, JL ;

McDonnell, SK ;

Frost, MH ;

Jenkins, RB .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (02) :77-84

[6] Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation [J].

Meijers-Heijboer, EJ ;

Verhoog, LC ;

Brekelmans, CTM ;

Seynaeve, C ;

Tilanus-Linthorst, MMA ;

Wagner, A ;

Dukel, L ;

Devilee, P ;

van den Ouweland, AMW ;

van Geel, AN ;

Klijn, JGM .

LANCET, 2000, 355 (9220) :2015-2020

← 1 →